The DOI matches its Crossref record.
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study
Abstract
Objectives: To determine whether patients with primary Sjögren's syndrome (SS), diagnosed according to San Diego criteria, had improvement in their laboratory or clinical features during treatment with hydroxychloroquine (6–7 mg/kg/day) for at least two years., Methods: The study population included 50 consecutive patients with primary SS who were diagnosed according to San Diego criteria, and in whom hydroxychloroquine was suggested as treatment. This group included 10 patients who were early dropouts (side effects or desire not to take antimalarial drugs) and 40 patients who received drugs for at least two years (range 24-48 months). In a subset of SS patients, values for ESR (westergren) and quantitative immunoglobulins were available for comparison. Improvement with therapy was defined as: (a) ≥20% improvement in variables of tear flow (Schirmer's test I) or corneal integrity (rose Bengal): (b) ≥20% salivary function (flow rate); and (c) improvement in at least two of the following measures: physicians assessment of global disease activity by ≥ 20%, patient assessment of improvement in pain or fatigue by ≥20%, and ESR improved by ≥20mm/ hr. Results: In a retrospective study of SS patients who completed the trial, a significant improvement was noted in ocular symptoms (pain and dryness) in patients (55 and 57%) and improved corneal integrity (rose Bengal straining) in 53% of patients. The Schirmer's test was improved by ≥ 2 mm/5 minutes in 50% in patients. Improvement was noted in oral symptoms (pain and dryness) in patients (57 and 60%) and salivary flow rate was increased in 82% of patients. In a subset of SS patients evaluated, the ESR improved by ≥20mm/hr in 17/32 patients (53%) and quantitative IgG level by ≥20% in 8/13 patients (61%). Physician global assessment of overall patient status and patient assessment of overall status indicated improvement in over 62% of patients. Conclusion: In a retrospective study of patients fulfilling San Diego Criteria for SS, we found: (a) sustained improvement of local symptoms (painful eyes, painful mouth) and improvement of systemic manifestations (arthralgias and myalgias) after treatment with hydroxychloroquine 6-7 mg/kg/day over mean three-year follow-up; (b) laboratory analysis showed a significant improvement in their ESR and their quantitative IgG levels; (c) no significant late toxicity was observed in this study cohort. A prospective study of hydroxychloroquine in patients fulfilling San Diego criteria for SS is indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Fox, R. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66990-5 · Cited by 1,828
Self-citationClinical Manifestations and Early Diagnosis of Sjögren Syndrome
Kassan, S. S., & Moutsopoulos, H. M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1275 · Cited by 698
Hydroxychloroquine: From Malaria to Autoimmunity
Ben-Zvi, I., Kivity, S., Langevitz, P., & Shoenfeld, Y. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8243-x · Cited by 613
Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M., & Kean, W. F. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0239-y · Cited by 543
Metadata
- Authors
- Fox, R., Dixon, R., Guarrasi, V, & Krubel, S.
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 1996-06
- Volume
- 5
- Issue
- 1_suppl
- Pages
- 31-36
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W4244409142
- Cited by
- 217
- References
- 0
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. https://app.cochat.ai/papers/10.1177/0961203396005001081
- The paper
- Fox, R., Dixon, R., Guarrasi, V, & Krubel, S. (1996). Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. https://doi.org/10.1177/0961203396005001081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.